Despite a modest 0.35% decline in the market index this month, there was a significant underlying market drawdown driven by rising capital costs. The 10-year Treasury yield, a key benchmark for long-term risk-free rates, surged above 5%, reflecting increased demand for capital. Notably, corporate insiders responded to falling stock prices by buying shares, particularly in retail, medical devices, aerospace & defense, and software sectors. This insider buying suggests confidence in these sectors despite broader market pressures and may influence future market stability.
The CDT insider sentiment for September 2026 is presented here with Pluang's market data as of Oct 06, 2026 03:12 WIB. Among 150 priced US stocks tradable on Pluang, 86 rose and 64 fell today. Notable movers include Opendoor Technologies Inc at USD 2.31 with a 1-day change of -5.33% and 99% sell order activity, Alibaba Group at USD 110.87 with a 1-day change of +4.74% and 44% buy order activity, and IQIYI Inc - ADR at USD 0.99 with a 1-day change of -3.94% and 100% buy order activity.
Revvity's stock has surged 56.1% year-to-date, outperforming its industry and the S&P 500, driven by an 11% organic revenue growth in diagnostics, especially in reproductive health and immunodiagnostics. Analysts from William Blair and Zacks have upg...
Levi Strauss & Co. is set to report its Q3 2026 earnings on October 7, with analysts forecasting adjusted earnings of $0.36 per share and revenue of $1.61 billion, marking a 4.5% increase year-over-year. Strong denim demand and growth in Europe, Asia...
On October 5, 2026, five notable stocks experienced double-digit declines. Sphere Entertainment fell 13.6% after a downgrade from Craig-Hallum, while C.H. Robinson dropped 10.9% following its announcement to acquire RXO for $5.8 billion. Velo3D, Boos...
Applied Digital is set to report a fiscal Q1 loss of $0.30 per share on $116.3 million revenue, reflecting ongoing investments in AI and high-performance data centers. The company has expanded its Polaris Forge 1 campus to 250 MW operational capacity...
Investment firm Needham increased its price target for Vaxcyte to $122 from $110 following positive Phase 3 trial results for Vaxcyte's VAX-31 pneumococcal vaccine. The vaccine met all primary endpoints in the OPUS-1 trial, showing noninferiority to ...
